From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Heavily pretreated patients with relapsed or refractory HL who received fludarabine-based lymphodepletion followed by CD30 CAR-Ts had a high rate of durable responses with an excellent safety profile, highlighting the feasibility of extending CAR-T cell therapies beyond canonical B-cell malignancies.

Journal of Clinical Oncology
Advertisement
News & Literature Highlights
Advertisement
Advertisement